Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01112514
Recruitment Status : Completed
First Posted : April 28, 2010
Results First Posted : February 24, 2014
Last Update Posted : February 24, 2014
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Damon Runyon Cancer Research Foundation
Information provided by (Responsible Party):
Andrew T. Chan, MD, MPH, Massachusetts General Hospital

Brief Summary:
Standard white light endoscopy involves the passage of a thin, flexible camera into the colon from the anus. Although standard white light endoscopy can detect most polyps and precancerous areas in the gastrointestinal tract and colon, many studies have shown that even the most experienced doctors, under optimal conditions, can miss up to 15-25% of precancerous areas. Thus, there remains a clear need to develop new methods of improving standard white light endoscopy. We are investigating whether indocyanine green (ICG) can serve to highlight areas which are precancerous when the colon is visualized with a special cameral which shines fluorescent light. Information from other studies suggests that this ICG agent may help to visualize blood vessels flowing to precancerous areas in the colon. We are looking at the ability of ICG, in combination with an endoscope which shines fluorescent light, to visualize precancerous areas in the colon.

Condition or disease Intervention/treatment Phase
High Risk Polyposis Syndrome Distal Colonic Lesions Colorectal Polyps Drug: indocyanine green Not Applicable

Detailed Description:
  • Participants will be scheduled for their regular lower endoscopy. On the day of the procedure, participants will come to the endoscopy unit at Massachusetts General Hospital. After arriving, participants will receive an intravenous line and meet with the research doctor to go over the procedure. The participant will then be transferred to the endoscopy procedure room and be administered sedatives until they are comfortable to proceed with the procedure.
  • The research doctor will pass the flexible study sigmoidoscope into the lower part of the rectum. At this time, a dose of the ICG contrast agent will be administered through the intravenous line. Any areas that are suspicious will be photographed using the camera in the scope. We will also biopsy/remove any suspicious areas and send it to the pathologist as we normally do during endoscopy.
  • Over the course of the study procedure, small doses of ICG will be administered to help find any precancerous areas. Altogether, the study exam should not take more than 10 to 15 minutes.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Pilot Study of Indocyanine Green Fluorescent Molecular Imaging of the Gastrointestinal Tract
Study Start Date : February 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : April 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: ICG Injection
These participants underwent a colonoscopy after having an ICG injection.
Drug: indocyanine green
Administered intravenously during endoscopic near-infrared (NIR) imaging
Other Names:
  • ICG
  • IC-Green

Primary Outcome Measures :
  1. Number of Neoplastic Lesions Detected [ Time Frame: upto 15 mins ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants will include patients with high risk polyposis syndromes with planned routine endoscopic surveillance for neoplasia or patients with planned endoscopic evaluation of distal colonic lesions suspicious for colorectal polyps or cancer detected on abdominal imaging
  • Fit for conscious sedation or monitored anesthesia care for colonoscopy-American Society of Anesthesiologists (ASA) Class I or II
  • 18 years of age or older
  • Eastern Cooperative Oncology Group (ECOG) Performance status 0-2
  • Negative human chorionic gonadotropin (HCG) test for women of child-bearing age. Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation

Exclusion Criteria:

  • Participants with AsA class III, IV, V
  • Documented allergy to iodine, iodine-containing compounds of ICG
  • Documented allergy to sulfur containing compounds
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ICG
  • History of adverse reactions to endoscopy or sedatives for endoscopy
  • Pregnant or breast-feeding women
  • Participants who are unable to discontinue warfarin anticoagulation 5 days before the procedure
  • Participants taking phenobarbital, phenylbutazone, primidone, phenytoin, haloperidol, nitrofurantoin, probenecid

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01112514

United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Massachusetts General Hospital
Boston, Massachusetts, United States, 02214
Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Damon Runyon Cancer Research Foundation
Principal Investigator: Andrew T. Chan, MD, MPH Massachusetts General Hospital

Responsible Party: Andrew T. Chan, MD, MPH, Study Principal Investigator, Massachusetts General Hospital Identifier: NCT01112514     History of Changes
Other Study ID Numbers: 09-398
First Posted: April 28, 2010    Key Record Dates
Results First Posted: February 24, 2014
Last Update Posted: February 24, 2014
Last Verified: January 2014

Keywords provided by Andrew T. Chan, MD, MPH, Massachusetts General Hospital:
indocyanine green